Pfizer Inc.’s top-selling COVID-19 vaccine and treatment left the company flush with cash to spend on acquisitions.
NEW YORK — Pfizer will spend about $5.4 billion to buy Global Blood Therapeutics as the pharmaceutical giant continues to invest some of the cash influx reaped during the COVID-19 pandemic.
Pfizer said Monday that the acquisition will boost its capabilities in rare hematology. Global Therapeutics makes Oxybryta tablets for treating sickle cell disease.
All news and articles are copyrighted to the respective authors and/or News Broadcasters. RockyDailyNews.Com is an independent Online News Aggregator
Read more from original source here…